GCAN
Greater Cannabis Company, Inc.
기간
0.20 USD
최근 종가 · 사전계산값
- PER (TTM)
- -
- PER (Forward)
- -
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.25
- 시가총액
- 189,081
- 배당수익률
- -
- 베타
- 0.39
- 1개월 수익률
- 13.76%
- 3개월 수익률
- 149.81%
- 6개월 수익률
- 100.10%
- 1년 수익률
- -46.64%
- 2년 수익률
- -
- 5일 평균거래량
- 6736
- 60일 평균거래량
- 6462
- 1년 평균거래량
- 3272
- 5d/60d 거래량 비율
- 1.04×
- 60d/1y 거래량 비율
- 1.98×
- 변동성(60일, 연환산)
- 519.47%
- BB 스퀴즈 스코어
- 0.27
- SMA50 비율
- 0.97
- SMA200 비율
- 0.98
- RSI (14)
- 53
- 20일 수렴도
- 0.10
- 52주 최고
- 0.60
- 52주 최저
- 0.05
- 고점 대비
- -66.65%
- 저점 대비
- 284.07%
펀더멘털 갱신: 2026-05-10T09:07:05+00:00 · 시세 갱신: 2026-05-10T06:36:19+00:00
회사 정보
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.